{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:05:06Z","timestamp":1790809506303,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"2024 Guangdong Provincial universities characteristic innovation project","award":["2024KTSCX078"],"award-info":[{"award-number":["2024KTSCX078"]}]},{"name":"2025 PSM Guangdong Pharmaceutical Science Research Fund","award":["2025KP26"],"award-info":[{"award-number":["2025KP26"]}]},{"name":"Hospital-level Education and Teaching Research Project of the Third Affiliated Hospital of Southern Medical University","award":["JXY202525"],"award-info":[{"award-number":["JXY202525"]}],"id":[{"id":"https:\/\/ror.org\/0050r1b65","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Special Research Project of the National Health Commission's Capacity Building and Continuing Education Center for 2025","award":["GWJJZX20251008037"],"award-info":[{"award-number":["GWJJZX20251008037"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"DOI":"10.1007\/s10067-026-08452-w","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:37:37Z","timestamp":1790761057000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sex-stratified disproportionality signals of adverse events with allopurinol and febuxostat: a retrospective pharmacovigilance analysis of FAERS and EudraVigilance"],"prefix":"10.1007","author":[{"given":"Yuting","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weitao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirou","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2539-2294","authenticated-orcid":false,"given":"Huancun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"10287","key":"8452_CR1","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"N Dalbeth","year":"2021","unstructured":"Dalbeth N, Gosling AL, Gaffo A et al (2021) Gout. Lancet 397(10287):1843\u20131855","journal-title":"Lancet"},{"issue":"6","key":"8452_CR2","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3904\/kjim.2020.340","volume":"36","author":"Y Waheed","year":"2021","unstructured":"Waheed Y, Yang F, Sun D (2021) Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease. Korean J Intern Med 36(6):1281\u20131293","journal-title":"Korean J Intern Med"},{"issue":"3","key":"8452_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2024.103796","volume":"35","author":"M Kuwabara","year":"2025","unstructured":"Kuwabara M, Hisatome I, Ae R et al (2025) Hyperuricemia, a new cardiovascular risk. Nutr Metab Cardiovasc Dis 35(3):103796","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"6","key":"8452_CR4","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T et al (2020) 2020 American College of Rheumatology Guideline for the Management of Gout[J]. Arthritis Care Res (Hoboken) 72(6):744\u2013760","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"8452_CR5","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/pds.5033","volume":"29","author":"R Panickar","year":"2020","unstructured":"Panickar R, Wo WK, Ali NM et al (2020) Allopurinol-induced severe cutaneous adverse drug reactions: Risk minimization measures in Malaysia[J]. Pharmacoepidemiol Drug Saf 29(10):1254\u20131262","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"8452_CR6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s43441-020-00245-w","volume":"55","author":"SC Lee","year":"2021","unstructured":"Lee SC, Wo WK, Yeoh HS et al (2021) Allopurinol-Induced Severe Cutaneous Adverse Drug Reactions: An Analysis of Spontaneous Reports in Malaysia (2000\u20132018)[J]. Ther Innov Regul Sci 55(3):514\u2013522","journal-title":"Ther Innov Regul Sci"},{"issue":"12","key":"8452_CR7","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/jcpt.13740","volume":"47","author":"PT Huong","year":"2022","unstructured":"Huong PT, Ha TN, Nhu T et al (2022) Allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: signal detection and preventability from Vietnam National pharmacovigilance database. J Clin Pharm Ther 47(12):2014\u20132019","journal-title":"J Clin Pharm Ther"},{"issue":"50","key":"8452_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1310\/hpj5003-189","volume":"3","author":"MA Mancano","year":"2015","unstructured":"Mancano MA (2015) Risk Factors for Androgen Deficiency with Daily Opioid Use; Co-trimoxazole and Sudden Cardiac Death in Patients Receiving ACE Inhibitors; Clindamycin-Induced Myelosuppression; Apixaban-Induced Diffuse Alveolar Hemorrhage; DRESS Syndrome Induced by Allopurinol[J]. Hosp Pharm 3(50):189\u2013193","journal-title":"Hosp Pharm"},{"issue":"1","key":"8452_CR9","doi-asserted-by":"publisher","first-page":"30742","DOI":"10.1038\/s41598-025-16062-w","volume":"15","author":"HT Pham","year":"2025","unstructured":"Pham HT, Tran MH, Mai Hoang TV et al (2025) HLA-B*58:01 genotyping prevalence and the association with allopurinol-induced severe cutaneous adverse reactions: a living systematic review and meta-analysis[J]. Sci Rep 15(1):30742","journal-title":"Sci Rep"},{"issue":"7","key":"8452_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/FPC.0000000000000285","volume":"27","author":"N Saksit","year":"2017","unstructured":"Saksit N, Tassaneeyakul W, Nakkam N et al (2017) Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population[J]. Pharmacogenet Genomics 27(7):255\u2013263","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"8452_CR11","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.jaip.2018.11.039","volume":"7","author":"JS Shim","year":"2019","unstructured":"Shim JS, Yun J, Kim MY et al (2019) The presence of HLA-B75, DR13 homozygosity, or DR14 additionally increases the risk of allopurinol-induced severe cutaneous adverse reactions in HLA-B*58:01 carriers. J Allergy Clin Immunol Pract 7(4):1261\u20131270","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"8452_CR12","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1111\/cts.12964","volume":"14","author":"T Sato","year":"2021","unstructured":"Sato T, Cheng CL, Park HW et al (2021) Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study[J]. Clin Transl Sci 14(3):1002\u20131014","journal-title":"Clin Transl Sci"},{"issue":"51","key":"8452_CR13","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1310\/hpj5111-884","volume":"11","author":"MA Mancano","year":"2016","unstructured":"Mancano MA (2016) ISMP Adverse Drug Reactions: Sildenafil-Induced Erythema Multiforme Acute Liver Injury Due to Febuxostat Intravenous Acetaminophen-Induced Acute Hepatotoxicity Acute Transient Myopia Induced by Zanamivir Lidocaine-Induced Hoigne Syndrome[J]. Hosp Pharm 11(51):884\u2013887","journal-title":"Hosp Pharm"},{"issue":"3","key":"8452_CR14","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/hep.28403","volume":"63","author":"M Bohm","year":"2016","unstructured":"Bohm M, Vuppalanchi R, Chalasani N (2016) Febuxostat-induced acute liver injury. Hepatology 63(3):1047\u20131049","journal-title":"Hepatology"},{"issue":"9","key":"8452_CR15","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/acr.25547","volume":"77","author":"W Sun","year":"2025","unstructured":"Sun W, Cui L, Terkeltaub R et al (2025) Risk of hepatotoxicity in patients with gout treated with febuxostat or benzbromarone: a propensity score-matched cohort study. Arthritis Care Res (Hoboken) 77(9):1149\u20131156","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"18","key":"8452_CR16","doi-asserted-by":"publisher","first-page":"6089","DOI":"10.3390\/jcm12186089","volume":"12","author":"Y Bai","year":"2023","unstructured":"Bai Y, Wu B, Gou L et al (2023) Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System. J Clin Med 12(18):6089","journal-title":"J Clin Med"},{"key":"8452_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.891606","volume":"9","author":"CL Cheng","year":"2022","unstructured":"Cheng CL, Yen CT, Su CC et al (2022) Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients. Front Cardiovasc Med 9:891606","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"8452_CR18","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jfma.2025.05.040","volume":"125","author":"TL Yang","year":"2026","unstructured":"Yang TL, Leu HB, Lin SJ et al (2026) Cardiovascular outcomes of febuxostat and allopurinol: a long-term Taiwanese nationwide cohort study. J Formos Med Assoc 125(5):574\u2013583","journal-title":"J Formos Med Assoc"},{"issue":"5","key":"8452_CR19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/1759720X11416405","volume":"3","author":"I Garcia-Valladares","year":"2011","unstructured":"Garcia-Valladares I, Khan T, Espinoza LR (2011) Efficacy and safety of febuxostat in patients with hyperuricemia and gout[J]. Therapeutic advances in musculoskeletal disease 3(5):245\u2013253","journal-title":"Therapeutic advances in musculoskeletal disease"},{"issue":"9","key":"8452_CR20","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1177\/0091270008322035","volume":"48","author":"R Khosravan","year":"2008","unstructured":"Khosravan R, Kukulka MJ, Wu JT et al (2008) The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 48(9):1014\u20131024","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"8452_CR21","doi-asserted-by":"publisher","first-page":"372","DOI":"10.5414\/CP203898","volume":"59","author":"T Wakabayashi","year":"2021","unstructured":"Wakabayashi T, Ueno S, Nakatsuji T et al (2021) Safety profiles of new xanthine oxidase inhibitors: A post-marketing study[J]. Int J Clin Pharmacol Ther 59(5):372\u2013377","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"8452_CR22","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1080\/17425255.2025.2481891","volume":"21","author":"EL Bosch","year":"2025","unstructured":"Bosch EL, Sommer IEC, Touw DJ (2025) The influence of female sex and estrogens on drug pharmacokinetics: what is the evidence?[J]. Expert Opin Drug Metab Toxicol 21(6):637\u2013647","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"8452_CR23","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/cancers17071054","volume":"17","author":"J Canzian","year":"2025","unstructured":"Canzian J, Conforti F, Jacobs F et al (2025) Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic Responses. Cancers (Basel) 17(7):1054","journal-title":"Cancers (Basel)"},{"key":"8452_CR24","unstructured":"Administration U S F A. Questions and answers on FDA's adverse event reporting system (FAERS)[EB\/OL][EB\/OL]. https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers.\u00a0Accessed 1 Sept 2026"},{"key":"8452_CR25","unstructured":"Agency E M. EudraVigilance: European database of suspected adverse drug reaction reports[EB\/OL][EB\/OL]. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/pharmacovigilance-research-development\/eudravigilance.\u00a0Accessed 1 Sept 2026"},{"key":"8452_CR26","unstructured":"ICH. MedDRA term selection: points to consider[EB\/OL][EB\/OL]. https:\/\/www.meddra.org\/how-to-use\/points-to-consider.\u00a0Accessed 1 Sept 2026"},{"issue":"2","key":"8452_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nbt.2113","volume":"30","author":"R B\u00f6hm","year":"2012","unstructured":"B\u00f6hm R, H\u00f6cker J, Cascorbi I et al (2012) OpenVigil\u2014free eyeballs on AERS pharmacovigilance data[J]. Nat Biotechnol 30(2):137\u2013138","journal-title":"Nat Biotechnol"},{"issue":"6","key":"8452_CR28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B et al (2024) The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement[J]. Drug Saf 47(6):575\u2013584","journal-title":"Drug Saf"},{"key":"8452_CR29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ijcard.2020.06.032","volume":"320","author":"T Akhtar","year":"2020","unstructured":"Akhtar T, Fratti J, Mattumpuram J et al (2020) Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: A real-world experience[J]. Int J Cardiol 320:78\u201382","journal-title":"Int J Cardiol"},{"issue":"21","key":"8452_CR30","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1002\/sim.2473","volume":"25","author":"GN Nor\u00e9n","year":"2006","unstructured":"Nor\u00e9n GN, Bate A, Orre R et al (2006) Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events[J]. Stat Med 25(21):3740\u20133757","journal-title":"Stat Med"},{"issue":"16","key":"8452_CR31","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"7","author":"MJLRE Dehlin","year":"2020","unstructured":"Dehlin MJLRE (2020) Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors[J]. Nat Rev Rheumatol 7(16):380\u2013390","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"8452_CR32","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1016\/S2665-9913(24)00117-6","volume":"6","author":"M Cross","year":"2024","unstructured":"Cross M, Ong KL, Culbreth GT et al (2024) Global, regional, and national burden of gout, 1990\u20132020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021[J]. Lancet Rheumatol 6(8):e507\u2013e517","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"8452_CR33","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1186\/s12891-024-08180-9","volume":"25","author":"KM Asghari","year":"2024","unstructured":"Asghari KM, Zahmatyar M, Seyedi F et al (2024) Gout: global epidemiology, risk factors, comorbidities and complications: a narrative review[J]. BMC Musculoskelet Disord 25(1):1047","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"8452_CR34","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","volume":"9","author":"L Du","year":"2024","unstructured":"Du L, Zong Y, Li H et al (2024) Hyperuricemia and its related diseases: mechanisms and advances in therapy[J]. Signal Transduct Target Ther 9(1):212","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"8452_CR35","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/00029330-200804020-00019","volume":"121","author":"T Martin","year":"2008","unstructured":"Martin T, Li H (2008) Severe cutaneous adverse drug reactions: a review on epidemiology, etiology, clinical manifestation and pathogenesis[J]. Chin Med J (Engl) 121(8):756\u2013761","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"8452_CR36","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/cts.13497","volume":"16","author":"J Hindi","year":"2023","unstructured":"Hindi J, Pilon MO, Meloche M et al (2023) Females present higher dose-adjusted drug concentrations of metoprolol and allopurinol\/oxypurinol than males. Clin Transl Sci 16(5):872\u2013885","journal-title":"Clin Transl Sci"},{"issue":"2","key":"8452_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s40263-021-00794-0","volume":"35","author":"I Alfares","year":"2021","unstructured":"Alfares I, Javaid MS, Chen Z et al (2021) Sex differences in the risk of cutaneous adverse drug reactions induced by antiseizure medications: a systematic review and meta-analysis. CNS Drugs 35(2):161\u2013176","journal-title":"CNS Drugs"},{"issue":"1","key":"8452_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2016","unstructured":"Richette P, Doherty M, Pascual E et al (2016) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76(1):29\u201342","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"8452_CR39","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jbspin.2016.10.004","volume":"84","author":"E Pascual","year":"2017","unstructured":"Pascual E, Andr\u00e9s M, V\u00e1zquez-Mellado J et al (2017) Severe gout: strategies and innovations for effective management. Joint Bone Spine 84(5):541\u2013546","journal-title":"Joint Bone Spine"},{"issue":"3","key":"8452_CR40","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/jcpt.12144","volume":"39","author":"Y Kang","year":"2014","unstructured":"Kang Y, Kim MJ, Jang HN et al (2014) Rhabdomyolysis associated with initiation of febuxostat therapy for hyperuricaemia in a patient with chronic kidney disease. J Clin Pharm Ther 39(3):328\u2013330","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"8452_CR41","volume":"16","author":"A Balidemaj","year":"2024","unstructured":"Balidemaj A, Kholoki S (2024) Rhabdomyolysis Associated With Febuxostat in a Non-Chronic Kidney Disease (CKD) Patient: Diagnostic and Management Challenges[J]. Cur\u0113us (Palo Alto, CA) 16(6):e63303","journal-title":"Cur\u0113us (Palo Alto, CA)"},{"issue":"12","key":"8452_CR42","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s40266-022-00986-3","volume":"39","author":"EH Kang","year":"2022","unstructured":"Kang EH (2022) Considerations for choosing first-line urate-lowering treatment in older patients with comorbid conditions. Drugs Aging 39(12):923\u2013933","journal-title":"Drugs Aging"},{"issue":"13","key":"8452_CR43","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB, Saag KG, Becker MA et al (2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378(13):1200\u20131210","journal-title":"N Engl J Med"},{"issue":"4","key":"8452_CR44","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cnur.2023.06.003","volume":"58","author":"KM Elertson","year":"2023","unstructured":"Elertson KM, Morgan LL (2023) Consideration of gender in cardiovascular disease prevention and management. Nurs Clin North Am 58(4):595\u2013605","journal-title":"Nurs Clin North Am"},{"key":"8452_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2023.116385","volume":"339","author":"K Lee","year":"2023","unstructured":"Lee K, Rushovich T, Gompers A et al (2023) A Gender Hypothesis of sex disparities in adverse drug events[J]. Soc Sci Med 339:116385","journal-title":"Soc Sci Med"},{"issue":"2","key":"8452_CR46","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cpt.1833","volume":"108","author":"R Gini","year":"2020","unstructured":"Gini R, Sturkenboom M, Sultana J et al (2020) Different Strategies to Execute Multi-Database Studies for Medicines Surveillance in Real-World Setting: A Reflection on the European Model[J]. Clin Pharmacol Ther 108(2):228\u2013235","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"8452_CR47","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/sim.8457","volume":"39","author":"X Wang","year":"2020","unstructured":"Wang X, Li L, Wang L et al (2020) Propensity score-adjusted three-component mixture model for drug-drug interaction data mining in FDA adverse event reporting system. Stat Med 39(7):996\u20131010","journal-title":"Stat Med"},{"issue":"2","key":"8452_CR48","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11096-023-01694-7","volume":"46","author":"M Tobaiqy","year":"2024","unstructured":"Tobaiqy M, Elkout H (2024) Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database. Int J Clin Pharm 46(2):488\u2013495","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"8452_CR49","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/14740338.2023.2243220","volume":"23","author":"Z Li","year":"2024","unstructured":"Li Z, Zou W, Yuan J et al (2024) Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system. Expert Opin Drug Saf 23(6):763\u2013770","journal-title":"Expert Opin Drug Saf"},{"key":"8452_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101425","volume":"48","author":"J Wang","year":"2022","unstructured":"Wang J, Zhang X, Geng X et al (2022) Risk of hepatitis B virus reactivation following treatment with abatacept: a retrospective study of international pharmacovigilance databases. eClinicalMedicine 48:101425","journal-title":"eClinicalMedicine"},{"issue":"47","key":"8452_CR51","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40264-023-01366-5","volume":"1","author":"C Micale","year":"2024","unstructured":"Micale C, Golder S, O\u2019Connor K et al (2024) Patient-reported reasons for antihypertensive medication change: a quantitative study using social media. Drug Saf 1(47):81\u201391","journal-title":"Drug Saf"},{"issue":"6","key":"8452_CR52","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1177\/0018578720934972","volume":"56","author":"A Lavu","year":"2021","unstructured":"Lavu A, Thiriveedi S, Thomas L et al (2021) Clinical utility of HLA-B*58:01 genotyping to prevent allopurinol-induced SJS\/TEN. Hosp Pharm 56(6):660\u2013663","journal-title":"Hosp Pharm"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08452-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08452-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08452-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:53:13Z","timestamp":1790808793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08452-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":52,"alternative-id":["8452"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08452-w","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}